BACKGROUND: Direct oral anticoagulants (DOACs) are surpassing warfarin as the anticoagulant of choice for stroke prevention in nonvalvular atrial fibrillation. DOAC outcomes in elective periprocedural settings have not been well elucidated and remain a source of concern for clinicians. The aim of this meta-analysis was to evaluate the periprocedural safety and efficacy of DOACs versus warfarin in patients with nonvalvular atrial fibrillation.
A
ccording to the Centers for Disease Control and Prevention, at least 2.7 million people in the United States have nonvalvular atrial fibrillation (NVAF), of whom at least 250 000 or an estimated 12% to 15% annually require evaluation for a procedure or surgery. 1, 2 Warfarin, a vitamin K antagonist, has recently been replaced by the direct oral anticoagulants (DOACs) as the first-line oral anticoagulant treatment option for stroke prevention in atrial fibrillation. 3 Warfarin, the half-life of which is long and variable (36-60 hours), is typically withheld 5 days before an elective procedure or surgery with the aim of targeting an international normalized ratio value <1.5 before the procedure or surgery. 4, 5 The DOACs have shorter half-lives and more predictable pharmacokinetics/pharmacodynamics, potentially enabling their interruption closer to the time of the procedure or surgery without the need for confirmatory laboratory testing of residual anticoagulant activity. The optimal DOAC periprocedural management strategy is a subject of debate among clinicians and has yet to be elucidated. 6, 7 Proponents of a pharmacokinetic/pharmacodynamic approach argue that simply stopping a DOAC before an elective procedure or surgery on the basis of the half-life of the drug (usually 1-2 days before) is a safe and effective approach and has the potential to greatly simplify periprocedural oral anticoagulant management. 7 Nonetheless, there is a scarcity of robust evidence to support the pharmacokinetic/pharmacodynamic strategy, coupled with concerns over its safety given the lack of a reliable laboratory marker of residual anticoagulant effect and the lack of specific antidotes for most DOACs. 6 The latest clinical practice guidelines on this topic from the American College of Chest Physicians in 2012 provide no recommendations, 2 and the most recent 2017 clinical decision pathways from the American College of Cardiology in the periprocedural management of DOACs in patients with NVAF provide suggestions only at the level of expert consensus. 8 Large phase III randomized controlled trials (RCTs) have compared the overall efficacy and safety of DOACs and warfarin in patients with NVAF. [9] [10] [11] [12] During the trials, many patients underwent elective procedures or surgeries, with the procedural outcomes data being reported in later substudies of the trials. The aim of this meta-analysis was to evaluate the periprocedural safety and efficacy of DOACs versus warfarin in patients with NVAF on the basis of the published phase III trials.
METHODS

Search Strategy and Data Sources
We performed an electronic database search through PubMed, Medline (via OVID), Google Scholar, and ClinicalTrials.gov for literature until March 2017 without any language restrictions. A list of the search key words is provided in Table I in the online-only Data Supplement. The search strategy and references from the latest version of the American College of Chest Physicians perioperative anticoagulation practice guidelines working group, 2 along with the 2017 American College of Cardiology expert consensus guidance statements on periprocedural management of NVAF, 8 were evaluated for completion. The references of all articles were also manually reviewed for additional trials.
Study Selection
All the studies were independently identified, reviewed, and screened by 2 authors (B.N. and B.P.) on the basis of their titles and abstracts in attempt to filter eligible studies. The authors performed a full-text review of the selected articles and used standardized sheets for data collection.
Studies were included if they were analyses or subanalyses of phase III prospective RCTs registered in ClinicalTrials.gov. Included studies met all of the following criteria: adult patients (≥18 years of age), invasive procedure or surgery, comparison
Clinical Perspective
What Is New?
• The shorter half-lives and more predictable pharmacokinetics/pharmacodynamics of direct oral anticoagulants (DOACs) can greatly simplify periprocedural oral anticoagulant management compared with warfarin, without the need for laboratory testing of residual anticoagulant activity.
• Robust evidence on the optimal DOAC periprocedural management strategy is lacking.
• This meta-analysis of 4 phase III randomized trials in nonvalvular atrial fibrillation that compared DOACs with warfarin assessed short-term periprocedural stroke/systemic embolism, major bleeding, and death between the 2 groups, mostly in elective procedural situations.
• In this largest study on the topic with ≈24 000 procedures and 19 500 patients, residual drug testing preprocedurally was not done for the DOACs.
What Are the Clinical Implications?
• There was no difference in stroke/systemic embolism, major bleeding, or death associated with procedures necessitating temporary interruption of the DOACs or warfarin.
• For procedures using an uninterrupted anticoagulation strategy, the DOACs group had a 38% lower risk of major bleeding compared with warfarin, with no differences in the risk of stroke/systemic embolism and death.
• The more predictable pharmacodynamics and pharmacokinetics of DOACs have the potential to simplify periprocedural anticoagulation management, to reduce interruption time off anticoagulation, and to provide no differences in short-term clinical outcomes of safety and efficacy compared with warfarin.
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of 2 groups with long-term use of warfarin or DOAC (apixaban, rivaroxaban, edoxaban, dabigatran) for NVAF periprocedurally, and 30-day postprocedural reporting of stroke/systemic embolism (SSE), major bleeding (MB), and death. Decisions on inclusion and exclusion were resolved by consensus among authors. Agreement between reviewers for study selection was assessed with the κ statistic. 13 The principal investigator (A.C.S.) addressed disagreements concerning study inclusion.
The study followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, and the selected articles were fully reviewed by all authors; however, 1 investigator (B.N.) performed data extraction. The corresponding authors of the studies that we found were contacted via e-mail for clarifications and missing data pieces. Retrieved data were reviewed and approved by the principal investigator. Disagreements related to study data extraction were resolved by consensus.
Data Extraction and Quality Assessment
Characteristics of the studies (first author, study design, region, year of publication, and inclusion criteria) were extracted into an Excel file after all relevant articles were identified. Demographic and baseline patient characteristics were collected for all included studies. The Excel file contained the total number of participants in each trial, the number of participants who underwent a procedure or surgery during the time period of the trial, and the corresponding total number of procedures.
The individual study outcomes were reported according to whether the oral periprocedural anticoagulant management followed an uninterrupted or interrupted strategy. Procedures were counted as being under an uninterrupted strategy if the study drug was continued in the periprocedural period or if 1 dose of the drug was skipped. Under the interrupted strategy, the oral anticoagulant was withheld before the procedure/surgery and restarted postprocedurally once hemostasis was achieved. Because data included in the meta-analysis originate from already published studies, Institutional Review Board approval was not required, and the analytical methods will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Outcomes
The primary outcomes of our meta-analysis were the 30-day rates of SSE (efficacy) and 30-day MB and death (safety) rates for DOACs as a group versus warfarin under the uninterrupted and interrupted strategies. We used the reported definitions of SSE as reported by the primary studies, which included stroke and systemic embolism. The latter was defined as an acute arterial occlusion of a peripheral artery. SSE did not include transient ischemic attack, myocardial infarction, or deep vein thrombosis/pulmonary embolism. We used the reported definitions of MB as defined by the primary trials, which included a decrease in hemoglobin level >2 g/dL, transfusion of ≥2 units of blood, or bleeding at a critical anatomic site ( 14 All studies defined death as all-cause mortality except RE-LY, in which cardiovascular death was used. We report the outcomes for each periprocedural anticoagulation strategy separately.
For the interrupted strategy, we assessed 2 additional secondary outcomes: 30-day MB rates according to the timing of study drug interruption before the procedure or surgery and 30-day SSE and MB rates according to the use of periprocedural heparin bridging therapy while the oral anticoagulant was withheld.
Statistical Analysis
Data were summarized with descriptive statistics, including means and 95% confidence intervals (CIs) for continuous variables and proportions for categorical variables. The overall relative risk (RR; DOACs versus warfarin) of efficacy and safety outcomes was estimated with a random-effects model. The I 2 test was used to assess heterogeneity in RRs among the studies. Pooled risks of adverse events for the DOAC group and warfarin group across the studies were calculated with the statistical method of Laird and Mosteller, 15 assuming fixed effects or random effects as appropriate. All analysis was performed with R version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Study Selection, Study Characteristics, and Study Quality
Our search strategy identified 127 studies after the removal of duplicate articles, of which 112 were excluded after screening the title and abstracts on the basis of the meta-analysis inclusion and exclusion criteria. The remaining 15 articles were reviewed in more detail. An additional 10 were excluded for a variety of reasons, including the lack of a formal statistical analysis, nonrandomized trial design, primary outcomes other than SSE and MB, and randomization of study drug during the periprocedural period. The search strategy yielded 4 phase III RCTs that met the inclusion criteria. [9] [10] [11] [12] The κ statistic of agreement between the 2 authors was 80%. Five substudies [16] [17] [18] [19] [20] of those trials provided periprocedural outcomes. Of note, there were 2 substudies of the RE-LY trial. 16, 17 Overall, the meta-analysis included outcomes of 24 024 procedures from 19 353 patients.
The baseline characteristics of the patients and procedures are presented in Table 1 . The mean age of patients ranged from 71 to73 years, and women represented ≈31% to 38% of the study populations. The mean creatinine clearance ranged from 68 to 80 mL/ min according to the Cockcroft-Gault method when such data were available. The mean CHADS 2 score ranged from 2.1 to 3. ORIGINAL RESEARCH ARTICLE halfway through the trial for discontinuation and reinitiation of study drug (dabigatran) for procedures or surgeries; the other studies left this decision to the discretion of the investigator. In all 4 trials, the proportions of patients who underwent a surgery or procedure were comparable between the DOAC and warfarin treatment groups (RE-LY, 25.1% versus 25.9%; ROCKET AF, 13.6% versus 16.2%; ARISTOTLE, 29.6% versus 30.2%; ENGAGE AF, 34.3% versus 33.7%). The types of procedures or surgeries in trial participants are shown in Table 2 and were comparable between the DOAC and warfarin groups. The 3 most common categories were gastrointestinal endoscopies (14.1%), dental or oral procedures (13.7%), and abdominal/ thoracic/orthopedic procedures (13.7%). Most of the procedures (≈95%) were elective. Table 3 shows the periprocedural anticoagulant strategy for the most common procedural categories.
Study Outcomes
Uninterrupted Periprocedural Anticoagulation Strategy Two trials (ARISTOTLE and ENGAGE AF) provided data for 7545 procedures under an uninterrupted strategy.
Overall Efficacy and Safety Outcomes
SSE events occurred in 29 of 4519 procedures among patients on DOACs (pooled incidence rate, 0.6%; 95% CI, 0.4-0.8) and 31 of 2971 procedures among patients on warfarin (pooled incidence rate, 1.1%; 95% CI, 0.7-1.4) at 30 days with no statistically significant difference in SSE between the 2 groups (RR, 0.70; 95% CI, 0.41-1.18; Table 4 and Figure 1A ). Of 4540 procedures in the DOAC group, 97 had MB (pooled incidence rate, 2.0%; 95% CI, 1.6-2.4) compared with a higher incidence of 98 of 2985 for the warfarin group (pooled incidence rate, 3.3%; 95% CI, 2.7-4.0; Table 4 ). The MB risk was 38% lower in patients receiving DOAC compared with those on warfarin (RR, 0.62; 95% CI, 0.47-0.82; Figure 1B) . There was no difference in the risk of death in the DOAC and warfarin groups (RR, 0.77; 95% CI, 0.53-1.12; Figure I in the online-only Data Supplement). The 2 study groups were homogeneous when SSE, MB, and death were compared (I 2 =0%).
Interrupted Periprocedural Anticoagulation Strategy
Substudies of all 4 trials reported the outcomes of 16 479 procedures for which the oral anticoagulant was discontinued before the procedure or surgery. 
=26.3%).
Outcomes According to Timing of Study Drug Interruption ARISTOLE, ROCKET AF, and RE-LY further stratified the MB outcomes according to the timing of the oral anticoagulant discontinuation before the procedure. Most 
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in the rate of MB (RR, 0.93; 95% CI, 0.61-1.40) in the DOAC group (42 of 891) compared with the warfarin group (43 of 855) in heparin-bridged patients. In nonbridged patients, there were no significant differences between the DOAC and warfarin groups for the pooled incidence rates of SSE (0.3% in both groups) and MB (1.6% versus 1.2%; Table III in the online-only Data Supplement). The 2 studies were highly homogenous (I 2 =0%) for both SSE and MB outcomes in the bridged and nonbridged groups. For both the DOAC and warfarin groups, bridging was associated with a 3-fold higher incidence of MB in the DOACs group and a 5-fold higher incidence in the warfarin group, whereas the pooled risk of SSE was ≈0.4% in both groups.
DISCUSSION
Our meta-analysis encompasses periprocedural data of ≈24 000 procedures from 19 500 patients with NVAF undergoing phase III RCTs who were on either a DOAC or warfarin and underwent an elective procedure or surgery. Our results show that both DOACs and warfarin were associated with low periprocedural adverse event rates of SSE, MB, and death. Under an uninterrupted periprocedural anticoagulation strategy, the pooled rate of MB at 30 days was 38% lower in DOAC-treated patients compared with those on warfarin (2.0% versus 3.3%), with no differences in the risk of 30-day SSE and death between the 2 groups. Under the interrupted strategy, there were no differences in the 30-day rates of SSE (≈0.4%), MB (≈2.0%), and death between the DOAC and warfarin groups. Drug interruptions within 1 day before a procedure were associated with an ≈50% lower risk of MB favoring the DOAC-treated patient group over the warfarin group, whereas MB outcomes of later interruptions seemed to favor warfarin.
The findings from this study are relevant for the growing body of patients who are on long-term DOACs for NVAF indications and require temporary interruption of their anticoagulant therapy for an elective procedure or surgery. There is an ongoing debate whether the simplicity of using a pharmacokinetic/pharmacodynamic approach to DOACs in periprocedural settings using the half-life of an individual drug (and other factors such as procedural bleed risk and patient renal function) may provide an optimal periprocedural approach compared with a more intensive approach of measuring the anticoagulant effects of a DOAC or its drug concentration to inform a periprocedural interruption strategy. 7 The phase III NVAF RCTs did not specify the use of DOAC drug levels or levels of DOAC-specific anticoagulant effects to inform study drug interruptions in periprocedural settings. These were left to the discretion of the treating investigator, or in the case of 1 open-label trial (RE-LY), a prespecified dabigatran periprocedural protocol was given to investigators to interrupt study drug halfway through the trial. Our large study strongly suggests that a periprocedural strategy of simply continuing a DOAC or interrupting it without the use of laboratory or drug assays is associated with an acceptably low periprocedural adverse event rate that is comparable to and in some cases safer than a similar strategy used for warfarin. These findings are supported by recent experiences of cohort studies with dabigatran and rivaroxaban in periprocedural settings that describe low rates of periprocedural adverse events using a simple pharmacokinetic/pharmacodynamic approach to DOAC management with a prespecified protocol based on patient renal function, perceived procedural bleed risk, and drug half-life. 21, 22 There is a growing body of evidence to suggest that many procedures can now be safely performed on patients using a strategy of either periprocedural continuation of oral anticoagulation (including many dental, ophthalmologic, dermatologic, endoscopic, and cardioverter-defibrillator device implantation procedures) or with discontinuation of anticoagulation close to the time of surgery. 7, 23 Our study showed a lower risk of MB favoring DOACs over warfarin and no significantly different rates of SSE and death in an uninterrupted oral anticoagulant strategy or with an interruption close to the time of procedure. This represents a potential advantage for DOACs over warfarin in the majority of patients undergoing procedures deemed minimal or low bleed risk, which constitute >80% of procedures assessed for periprocedural anticoagulant interruption. 24, 25 One explanation is the much shorter half-life of the DOACs as a class (7-14 hours) over warfarin (60 hours) that enables temporary discontinuation much closer to the time of the procedure or surgery. 8 In addition, DOACs as a class have more predictable pharmacokinetic and pharmacodynamic anticoagulant effects than warfarin, which may translate into fewer MBs in periprocedural settings. 26 For procedures requiring temporary interruptions of oral anticoagulant therapy, our study showed no differences of SSE, MB, and death for DOACs compared with warfarin, with low pooled incidence rates of SSE (0.4% for both) and MB (≈2.0% for both). These results compare favorably with results from the placebo group of the RCT BRIDGE trial (Perioperative Bridging Anticoagulation in Patients With Atrial Fibrillation) in patients with NVAF who required temporary interruption of warfarin, in which the rates of SSE (0.4%) and MB (1.3%) were similar to the rates seen for DOACs in our meta-analysis. 24 These results also compare favorably with the nonbridged group of a large meta-analysis conducted previously with patients on vitamin K antagonist therapy requiring temporary interruption, in whom the SSE rate was 0.8% and the MB rate was 1.4%. 27 Overall, these clinical outcomes data provide reassurance of the safety and efficacy of DOACs compared with well-managed warfarin in patients undergoing non-low-bleeding-risk procedures.
Last, we hypothesize the presence of an increased incidence of MB associated with heparin bridging therapy used with temporary interruptions of warfarin or DOACs in periprocedural settings without associated reductions in thromboembolic rates. We observe in our analysis a 3-to 5-fold increased incidence of MB with the use of heparin bridging therapy with either DOACs or warfarin and no associated reduction in the risk of SSE. These observational findings are consistent with previous reports, 17, 24, 27 including Level 1 evidence from the BRIDGE trial. 24 The incidence of periprocedural MB rate was ≈4 times that of SSE in the nonbridged group and >10 times that in the bridged group. Further conclusions on heparin bridging therapy based on our data set are limited by the lack of adjustment between the bridged and nonbridged groups, which are likely to have different characteristics.
Our meta-analysis has a number of potential limitations. First, the included RCT data originated from substudies, only 1 of which was prespecified (ENGAGE AF). 20 Second, the outcomes were presented for procedures rather than patients, with ROCKET AF 18 and ARISTOTLE 19 having had >1 procedure analyzed per patient. Third, analyses of outcomes under the uninterrupted strategy and according to bridging are from 2 trials only. Fourth, the definitions of MB used in all trials did not originate
ORIGINAL RESEARCH ARTICLE
from the same expert society, whereas the definition of SSE appeared more consistent across the trials. Fifth, the 4 trials had a large majority of patients with a normal kidney function, and >95% of procedures were elective. The applicability of our findings to reduced renal function and emergent procedural settings is therefore limited. Furthermore, the heterogeneity of the death outcome under the interrupted strategy is a limitation likely resulting from the discrepancies in the definitions and conventions for cause of death (all-cause versus cardiovascular) between trials. Despite these limitations, we believe that our metaanalysis has several points of strength. To the best of our knowledge, it is the largest periprocedural analysis of patients with NVAF on DOACs. The large sample size is especially important, considering the low event rates for both SSE and MB. The sample size was also large for analyses of 2 trials only, such as outcomes according to the uninterrupted strategy for which 7525 procedures were included. We believe that the randomization of trial participants should reliably reduce the effect of potential confounding variables between the 2 groups, although we acknowledge that the potential for unforeseen confounding exists because patients were not randomized by procedure or surgery. For all outcomes except 1 (death under the interrupted strategy), the results were highly homogeneous between trials. The outcomes were also externally consistent with many recent large meta-analyses on the subject and prospective randomized trials. Our results support the recent 2017 American College of Cardiology expert consensus guidance statements on periprocedural management of NVAF with recommendations for DOACs that are based on a pharmacokinetic/ pharmacodynamic approach. 8 For each DOAC, the recommendations rely on the patient's predicted renal clearance of the drug and the procedural bleed risk. In most scenarios, the DOAC can be safely interrupted ≥1 days before the procedure, with no need for residual drug effect testing preprocedurally. Our meta-analysis reveals that a simplified periprocedural anticoagulant management strategy with DOACs has periprocedural adverse outcomes that are not different from those with warfarin and the potential for a reduction in MB risk with shorter interruption times compared with warfarin.
Finally, we anticipate the results of the ongoing PAUSE trial (ClinicalTrials.gov NCT02228798). 28 This prospective multicenter trial aims to define a standardized perioperative DOAC management protocol for rivaroxaban, apixaban, and dabigatran in patients with NVAF and is expected to provide further high-level evidence on interruption times and residual anticoagulant effects of the DOACs.
CONCLUSIONS
We provide the largest analysis to date showing that a simple interruption of DOACs in patients with NVAF before an elective procedure or surgery is associated with excellent clinical outcomes of efficacy (SSE) and safety (MB and death) compared with warfarin. In scenarios in which the procedure did not require oral anticoagulant interruption, the DOACs had an ≈40% lower risk of MB compared with warfarin. The shorter half-life and more predictable pharmacokinetics and pharmacodynamics of DOACs have the potential to simplify periprocedural anticoagulation management and to reduce interruption time off anticoagulation.
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